Search results
Showing 376 to 381 of 381 results for lung cancer
For the first time, we have recommended a targeted treatment option for ALK-positive non-small-cell lung cancer, to be given after surgery to reduce the risk of the disease coming back.
NICE Board says new method allowing greater weight to be given to severe diseases is working
At today's meeting (25th September 2024) our board has concluded that the new severity modifier is working as intended.
Targeted treatment for rare form of aggressive lung cancer gets NICE approval
Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer
Dr Ravinder Claire outlines recent progress towards greater use of real-world evidence in regulatory decision-making. He also considers the implications and opportunities for NICE and our stakeholders.
Additional evidence needed to assess histology-independent cancer drugs
A paper published and co-authored by NICE staff looks at how histology-independent cancer drugs might be appraised.
Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.